Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Poxel
  6. News
  7. All News
    POXEL   FR0012432516

POXEL

(POXEL)
  Report
Real-time Quote. Real-time Euronext Paris - 06/11 11:39:02 am
7 EUR   +2.19%
06/01POXEL  : Corporate Presentation
PU
05/21Today on Wall Street: Poor manufacturing data boosts indexes
05/14POXEL  : Corporate Profile May 2021
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about POXEL
06/01POXEL  : Corporate Presentation
PU
05/21Today on Wall Street: Poor manufacturing data boosts indexes
05/14POXEL  : Corporate Profile May 2021
PU
05/05POXEL  : Corporate Presentation
PU
05/03POXEL  : Corporate Presentation
PU
04/22GLOBAL MARKETS LIVE : Chevron, Toyota, Sony...
03/31POXEL  : Corporate Profile March 2021
PU
03/25POXEL  : Announces availability of its 2020 Universal Registration Document
PU
03/25POXEL  : Document d'Enregistrement Universel 2020
PU
03/25POXEL  : Full Year 2020 Financial and Corporate Update
PU
03/24POXEL  : Full Year 2020 Financial and Corporate Presentation - English
PU
03/24POXEL  : Corporate Presentation - English
PU
03/24POXEL  : Reports Financial Results for Full Year 2020 and Provides Corporate Upd..
BU
03/15POXEL  : Corporate Presentation - English
PU
03/14POXEL  : Corporate Presentation
PU
03/12POXEL  : Corporate Presentation - English
PU
02/24POXEL  : Corporate Presentation - English
PU
02/24POXEL  : Announces Completion of Arbitration with Merck Serono
BU
02/19POXEL  : Corporate Presentation - English
PU
02/15POXEL  : Reports Financial Update for Cash and Revenue for the Full Year 2020 an..
AQ
02/12POXEL  : Reports Financial Update for Cash and Revenue for the Full Year 2020 an..
BU
01/15POXEL  : Corporate Presentation - English
PU
01/14POXEL  : Regains Imeglimin Rights From Metavant
BU
01/08POXEL  : Corporate Presentation - English
PU
01/07POXEL  : Corporate Presentation - English
PU
01/05POXEL  : Announces Financial Calendar for 2021
BU
2020POXEL  : Corporate Presentation - Engl
PU
2020POXEL  : Announces Participation at Upcoming Virtual Investor Conferences
BU
2020POXEL  : Corporate Presentation - English
PU
2020POXEL  : annonce des résultats positifs supplémentaires pour son étude de phase ..
PU
2020POXEL  : Announces Additional Positive Phase 2a Results, and Phase 2b Plan for P..
BU
2020POXEL  : Corporate Presentation - English
PU
2020POXEL  : to Host Virtual NASH Investor Event with Leading Experts on December 14..
BU
2020Poxel Provides Update on Metavant Partnership with Imeglimin
AQ
2020POXEL  : Corporate Presentation - English
PU
2020POXEL  : Partner Metavant Abandons Development of Diabetes Treatment
MT
2020POXEL  : Provides Update on Metavant Partnership with Imeglimin
BU
2020POXEL  : Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data ..
AQ
2020POXEL  : Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data ..
BU
2020POXEL  : Corporate Presentation - English
PU
2020POXEL  : Announces Upcoming Poster Presentations at AASLD The Liver Meeting® 202..
BU
2020Poxel Announces Participation at Several Upcoming Scientific and Investor Con..
AQ
2020POXEL  : Announces Participation at Several Upcoming Scientific and Investor Con..
BU
2020Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Qu..
AQ
2020POXEL  : Corporate Presentation - English
PU
2020POXEL  : Provides Corporate Update and Reports Cash and Revenue for the Third Qu..
BU
2020Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the Frenc..
AQ
2020POXEL  : Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the Frenc..
BU
2020POXEL  : Corporate Presentation - English
PU
2020POXEL  : Corporate Presentation - English
PU
2020POXEL  : Announces Positive Results from Phase 2a NASH Trial with PXL770, an Ora..
AQ
2020POXEL  : Announces Positive Results From Phase 2a NASH Trial With PXL770, an Ora..
BU
2020Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-..
AQ
2020POXEL  : Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-..
BU
2020Poxel Announces Participation at Upcoming Scientific and Investor Conferences
AQ
2020POXEL  : 2020 Half Year Financial Report
PU
2020POXEL  : Corporate Presentation - English
PU
2020POXEL  : Announces Participation at Upcoming Scientific and Investor Conferences
BU
2020Poxel Reports Financial Results for First Half 2020 and Provides a Corporate ..
AQ
2020POXEL  : 1H 2020 Financial and Corporate Presentation
PU
2020POXEL  : Reports Financial Results for First Half 2020 and Provides a Corporate ..
BU
2020POXEL  : to Host Conference Call for First Half 2020 Financial Results on Septem..
BU
2020POXEL  : Initiates Phase 2 NASH Trial for PXL065 (DESTINY 1) in Biopsy-Proven Pa..
BU
2020POXEL  : Corporate Presentation - English
PU
2020POXEL  : Announces Submission of Imeglimin Japanese New Drug Application for the..
BU
2020POXEL  : Provides Corporate Update and Reports Cash and Revenue for the Second Q..
BU
2020POXEL  : Corporate Presentation - English
PU
2020POXEL  : Announces Results from June 24, 2020 Ordinary Annual and Extraordinary ..
BU
2020POXEL  : Announces Positive Pharmacokinetic Pharmacodynamic Study Results for PX..
AQ
2020POXEL  : Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Re..
BU
2020POXEL  : Announces Participation in Upcoming Virtual Investor Conferences
BU
2020Poxel Successfully Raises EUR17.7 Million in a Capital Increase
AQ
2020POXEL  : Announces Program Update and Preclinical Results on PXL770 for NASH Com..
BU
2020POXEL  : Successfully Raises €17.7 Million in a Capital Increase
BU
2020POXEL  : Announces Notice of its Annual General Meeting to be Held on June 24, 2..
BU
1  2Next
Upcoming event on POXEL
06/16/21